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Background: Choosing between deep brain stimulation (DBS), Levodopa-Carbidopa
intestinal gel (LCIG), or continuous subcutaneous Apomorphine infusion (CSAI) in
advanced Parkinson’s disease is a complex decision. It is paramount to combine
evidence with the professional’s expertise and the patient’s preferences. The patient’s
preferences can be elicited and integrated into the treatment choice through shared
decision-making (SDM).
Objective: In this cross-sectional survey study we explored patient’s involvement in
decision-making and identified facilitators and barriers for shared decision-making (SDM)
in advanced Parkinson from the patient’s perspective.
Methods: We invited 180 Dutch persons with Parkinson who started DBS, LCIG, or
CSAI in the previous 3 years to complete a questionnaire. Questions covered three topics;
(1) preferred and experienced roles in the decision process for an advanced treatment, (2)
information needs to make a decision and actually received information, and (3) factors
that had positively or negatively influenced shared decision-making (SDM).
Results: One hundred and twenty one participants completed the questionnaire.
The large majority preferred to be involved in the decision-making (93%), and most
respondents had experienced an active role (85%). In about half of the respondents
(47%), their preferred role did not match their experienced role; 28% had a more
active role than they would have preferred. Although 77% perceived to be fully
informed at the time of decision, only 41% stated they knew all three therapeutic
options. Participants identified the most important facilitators for shared decision-making
(SDM) at the patient’s level (i.e., perceiving the decision to be his own choice),
at the neurologist’s level (i.e., having expertise on all treatment options, and taking
time for the decision), and within the professional-patient relationship (i.e., trust and
having an open discussion). The main barriers for shared decision-making (SDM)
existed at the patient’s level (i.e., perceiving there is no choice), neurologist’s level
(own treatment preference), and organizational level (i.e., no research available that
compares treatments, multiple professionals involved, and lack of consultation time).
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Conclusions: Patients want to be involved and feel involved when choosing an
advanced treatment, but often do not know all treatment options. Implementation of true
patient involvement needs personalized information provision on all treatment options
and improvement on how this information is communicated.
Keywords: advanced therapies, cross-sectional study, advanced parkinson’s disease, shared decision-making,
questionnaire
INTRODUCTION
Parkinson’s disease (PD) is a highly complex,
multidimensional disease. With disease progression, severe
motor and non-motor symptoms can develop with unpredictable
on- and off fluctuations and dyskinesia. When these motor
complications arise, advanced treatment options, including
deep brain stimulation (DBS), Levodopa-Carbidopa intestinal
gel (LCIG), and continuous subcutaneous Apomorphine
infusion (CSAI) are important to consider. Each of them
has specific advantages and disadvantages. Choosing a
therapy, therefore, requires a careful deliberation process,
in which the available scientific evidence, the clinician’s
expertise and the individual patient’s characteristics
and preferences are balanced and jointly guide the
decision (1).
The application of these evidence-based medicine principles
to this particular decision appears to be challenging in clinical
practice. First of all, unbiased and comparable information
for all three options is not straightforward, as no randomized
controlled trials have been conducted including all three
advanced treatments (2). Secondly, the clinician’s expertise is
often limited due to a lack of treatment experience or availability
of the advanced treatments at their hospital (3). Third, including
the patient’s individual preferences is recognized as an ethical
imperative, but it’s questionable to what extent patients are
actually actively involved (4, 5). To overcome the last challenge,
shared decision-making (SDM) can play a pivotal role (6).
SDM means that the neurologist and the patient identify the
decision to be made, share the treatment options and available
evidence, elicit the patient’s preferences and reach a shared
decision (6–8). PD patients in general have indicated that they
want to be more involved in clinical decision-making, but lack
sufficient information to do so (9). In contrast, professionals
often report that patients do not want to be involved in
decision-making, which seems to be more common in older
and less educated patients (10). More specifically, neurologists
mention limited decision-making capacity in PD patients as
an additional barrier to SDM in advanced PD, related to
disease severity, and associated cognitive deficits (5). Quantitative
studies investigating the patient’s perspective on involvement in
decision-making in this specific group of advanced PD patients
have not been conducted.
The objective of this study was to investigate the patient’s
perspective on; (1) the preferred and experienced level of
involvement in the decision process for an advanced treatment,
(2) the information needs and received information for this
decision, and (3) perceived facilitators and barriers for shared
decision-making for this specific decision.
MATERIALS AND METHODS
Questionnaire
The aim of the questionnaire was to systematically collect
experiences of the decision-making process for an advanced
treatment option. Previously conducted focus groups and
interviews with advanced PD patients treated with an advanced
therapy (CSAI, DBS, or LCIG) defined the content of the
questionnaire (5). Items covered socio-demographics plus
disease-related characteristics and three key topics; (1) role
preferences and experienced roles in the decision process, (2)
information needs to make a decision and actually received
information, and (3) factors that had positively or negatively
influenced shared decision-making (Supplement 1).
We recorded socio-demographics and disease-related
information: years of PD disease duration, year of starting
advanced treatment (in case of multiple advanced treatments,
year of starting last treatment), type of advanced treatment
received (multiple options possible), and disease severity
(self-reported Hoehn and Yahr score) (11).
To obtain information about the decision-making process, we
included the validated Control Preferences Scale (CPS), which
captured the role preference, and experienced role in decision-
making (12). This single item five-point scale consists of pictures
combined with descriptions displaying five roles of the patient
in decision-making (fully active, semi-active, collaborative, semi-
passive, fully passive). The participant was asked which role (s) he
would have wanted (preferred role) when the advanced therapy
was chosen and which role (s) he actually had (experienced role).
To evaluate the information received and the information needs,
we asked which options were known at the time of the decision
and how well-informed they felt on 22 information topics at
the time of the decision (5). To determine if information needs
and received information matched, we used the Importance
Performance Analysis (IPA) (13, 14). Patients first rated the
importance of each information attribute (the importance score)
on a five-point Likert scale (not important, of little importance,
neutral, important, very important). Next, they were asked
whether they received sufficient, insufficient or no information
on each attribute (the performance score). Finally, 33 items
about facilitators (n = 19) and barriers (n = 14) for SDM,
derived from our earlier study (5), were presented. For each
item we asked to what extent it had been a facilitator/barrier
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for shared decision-making, on a five-point Likert scale (no
opinion, no facilitator/barrier, small facilitator/barrier, moderate
facilitator/barrier, large facilitator/barrier). The facilitators and
barriers were divided into four categories (adapted from Grol
and Wensing) (15); professional’s level, patient’s level, the
professional-patient relationship level (social context level), and
the organizational level. The professional level represented both
the neurologist and PD nurse specialist, unless it was specifically
stated neurologist. Patients had the possibility to add facilitators
and barriers that were not included in the list. We designed
two versions of the questionnaire, in which the order of the
questions were different to prevent framing due to question
order (16).
The questionnaire was piloted in eight persons; four patients,
one expert in health education & communication, two lay people
and an industrial designer, specialized in consumer process
evaluation. Piloting addressed readability, comprehensibility and
time to complete the questionnaire. Based on their feedback, the
questionnaire was finalized.
Target Population and Recruitment
Eligibility criteria for patients to participate were: (1) diagnosis
of PD by a neurologist and (2) having started one of the
advanced treatments (CSAI, DBS, or LCIG) in the past 3
years. We recruited participants via 13 neurologists, working
in community (n = 4), regional (n = 4) and academic
(n = 5) hospitals. We used purposive sampling to select
neurologists with expertise on one or more advanced treatments
who could include eligible patients. Neurologists were asked
to send a paper-based questionnaire with a hyperlink to the
online questionnaire to all their patients who had started an
advanced therapy in the previous 3 years. To reduce a potential
selection bias by the neurologists, the Dutch Parkinson’s Disease
Association published a recruitment advertisement on their
website. Eligible patients could apply and subsequently received
the paper-based questionnaire and a hyperlink to the online
questionnaire. No reminders could be sent, as questionnaires
were processed anonymously.
Ethical Considerations
The regional medical ethical commission approved the study
(CMO Nijmegen-Arnhem, registration number 2011-085). We
asked all participants to give written informed consent prior to
completing the questionnaire.
Data Analysis
Data concerning the socio-demographics, disease characteristics
and the facilitators/barriers were analyzed descriptively with
frequencies and percentages. To investigate the congruence
between preferred and experienced role in the decision-making
process, we divided the number of participants whose preferred
and experienced role exactly matched by the total number
of participants. The mismatch and direction of mismatch
was calculated by counting the participants whose preferred
role differed from the experienced role in decision-making
(either preferred a more active or a more passive role than
experienced) divided by the total number of participants. We
analyzed group differences in gender, age, education, and
disease severity between the group with a matched role vs.
the group with a mismatch, using Pearson’s χ-square test or
Fisher exact test. We calculated the correlations between the
patients’ knowledge of existing treatment options (not knowing
all options vs. knowing all options) and whether they felt fully
informed (yes or no) at the time of decision using Pearson’s
χ-square test.
For the IPA analysis, the performance rates were recalculated
into a five-point Likert scale, allowing the comparison of the
importance scores with the performance scores for the IPA.
The mean importance score of all information attributes was
calculated, as well as the mean performance score of all attributes.
Subsequently, themean importance score andmean performance
TABLE 1 | Demographics and disease characteristics.
Sample size Value
Gender [men, n (%)] 111 68 (61)
Age in years [median (range)] 111 65 (38–84)
Work [n (%)] 110
Not working 88 (80)
Part-time job 17 (15)
Full-time job 5 (5)
Marital status [n (%)] 110
Single 22 (20)
Relation/married, living together 84 (76)
Relation, living apart 4 (4)
Education [n (%)] 109
Primary school 10 (9)
Secondary school 41 (38)
Lower vocational education 30 (27)
Higher education 28 (26)
PD disease duration [n (%)] 111
5–10 years 31 (28)
More than 10 years 80 (72)
Self-reported Hoehn and Yahr stage [n (%)] 109
0 3 (3)
1 13 (12)
2 9 (8)
3 52 (48)
4 24 (22)
5 8 (7)
Treatment [n (%)*] 111
CSAI 20 (18)
DBS 65 (59)
LCIG 42 (38)
Years of treatment 111
0–1 19
1–2 60
2–3 32
CSAI, continuous subcutaneous Apomorphine infusion; DBS, deep brain stimulation;
LCIG, Levodopa-Carbidopa intestinal gel. *The total number exceeds 111 as some
patients had undergone more than one of the advanced treatment options.
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TABLE 2 | Congruency between preferred and experienced roles in decision-making.
Experienced role
Patient
alone
Patient with
neurologist
input
Shared
decision
Neurologist
with patient
input
Neurologist
alone
Total
number of
patients (%)
Preferred role Patient alone 2 – – – – 2 (2)
Patient with neurologist input 7 12 6 – 2 27 (29)
Shared decision 4 13 31 8 1 57 (62)
Neurologist with patient input – – 2 3 – 5 (6)
Neurologist alone – – – – 1 1 (1)
Total number of patients (%) 13 (14) 25 (27) 39 (43) 11 (12) 4 (4) 92 (100)*
Preferred role is: the role a patient would have wanted in the decision-making process; perceived role is the role the patient has experienced in the decision-making process. Blue cells
are the cells that represent matched roles. *13 patients did not fill in a perceived role and six patients had invalid data for one or both questions on the roles in decision-making.
score for each information attribute separately was calculated. To
prioritize the attributes that need improvement, the attributes
were ranked on importance and performance using the mean
of each attribute on importance and compare it to the mean
importance score of all attributes together. Attributes that scored
higher than the mean importance of all attributes, and had
a mean performance score which was lower than the mean
importance score, require improvement (13, 14).
For all analyses, we used SPSS, version 25. Because of large
numbers of missing data for the facilitators and barriers, missing
value analysis was conducted using Pearson’s χ-square test or
Fisher exact test for analyzing differences between completers
and non-completers, without applying imputation methods.
RESULTS
A total of 121 patients completed the questionnaire. Most of them
(n = 112) replied to the invitation from the neurologists (171
invitations sent out; response rate 65%). Of these 121 completed
questionnaires, we excluded 10 (=8%) as they either did not
fill in the date when they had started the treatment (n = 6)
or the treatment started more than 3 years ago (n = 4). The
remaining 111 questionnaires were included for analysis. Forty
percent of the participants had filled in the questionnaire alone,
46% with their partner, and 13% with someone else (mostly a
family member). One participant had not filled in this question.
See Table 1 for demographics and disease characteristics.
Roles in Decision-Making
In retrospect, the vast majority preferred to have been actively
involved in the decision-making process; 31% of the participants
wanted to decide themselves and 62% wanted it to be a shared-
decision together with their neurologist. Many patients also had
experienced an active role; 41% perceived they had decided
themselves and 43% experienced shared decision-making. Half
of the respondents (47%) experienced a mismatch between their
preferred and experienced role in decision-making (Table 2). In
those cases where there was a mismatch, 28% of the respondents
experienced a more active role in the decision-making process
than preferred, and 19% experienced a less active role than
TABLE 3 | Degree of known advanced treatment options.
Known treatments before decision
Chosen treatment CSAI DBS LCIG Total
CSAI 7 (88) 3 (38) 3 (38) 8 (9)
DBS 29 (53) 54 (98) 32 (58) 55 (58)
LCIG 14 (45) 23 (74) 28 (90) 31 (33)
Total 50 (58) 80 (83) 63 (69) 94 (100)
Patients could have knowledge of more than one treatment, therefore percentages
of known treatments are more than 100 percent. CSAI, continuous subcutaneous
Apomorphine infusion; DBS, deep brain stimulation; LCIG, Levodopa/Carbidopa
intestinal gel.
preferred. Of those who would have preferred a less active role,
the majority (62%) had a preference for shared decision-making
but experienced that they had made the decision themselves.
Among the patients that would have preferred a more active
role, 65% preferred shared decision making but experienced that
the neurologist took the decision for them. The patients who
experienced a match between their preferred and experienced
role in the decision-making process did not differ from patients
who experienced a mismatch, in terms of gender, age, education,
or disease severity.
Knowledge, Information Needs, and
Information Support
Although the majority of patients (77%) felt fully informed
at the time of the decision, only 41% was aware of all three
treatment options. Overall, DBS was the best-known treatment,
with 83% knowing this option before the decision was made.
LCIG was second with 69% and 58% of the patients knew CSAI
was an option. CSAI patients were the least informed about
the alternative options (Table 3). In each treatment group, a
few patients (CSAI and DBS one patient; LCIG three patients)
indicated that they did not know the treatment they eventually
started. Knowing all options was not associated with feeling fully
informed [X2
(1)
= 0.001, p= 0.590].
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When asked to indicate how important they valued the
information attributes (importance) and whether or not they
had received enough information on these attributes to
make a decision (performance), all attributes were found to
be important, except for information on contra-indications
(<50% of respondents). Information about effects of the
advanced treatments on quality of life was found to be most
important. The IPA analysis identified nine out of the 22
information attributes that were considered to be important,
while information provision had been inadequate (Figure 1). The
lowest performance scores were given for information on long
term effects and psychological effects of the advanced treatments.
Facilitators and Barriers to Shared
Decision-Making
Among the five most important facilitators for SDM, two related
to the professional: (1) the experience of the neurologist with the
treatments (89% of patients considered this to be a moderate-
to-large facilitator), and (2) the neurologist taking time for the
decision (83%). Two factors related to the professional and
patient interaction: (1) trust between the patient and professional
(84%), and (2) an open discussion between the patient and
professional (80%). One facilitator related to the patient: the
patient considering the decision his own choice (83%).
Participants ranked barriers frequently as no barrier (on
average 54% per barrier, range 43–66%) or had no opinion (on
average 22%, range 12–35%). The five most important barriers
were more diverse as they related to the patient, the professional,
and the organizational level. Patients identified the perception
of having no choice as the most important barrier (24% of
respondents considered this a moderate to large barrier). The
professional having his own preference for a treatment (23%)
was the barrier at the professional level. Furthermore, three
factors at the organizational level emerged: (1) lack of time at the
consultation to discuss the options (21%), (2) not having the same
professional involved during the decision process (19%), and (3)
the lack of research to compare the treatments (22%).
On average, barriers had 12% missing values (range 10–14%)
and for the facilitators this was 13% (range 10–16%). The missing
value analysis showed that two patients had not ranked any
of the facilitators or barriers. Ten respondents had more than
50% percent missing values for both the barriers and facilitators.
This group of 10 respondents did not differ from the other 101
respondents in terms of age, educational level, or disease severity.
There were relatively more women in the group with more than
50% missing values compared to the other group (p = 0.44,
Fisher’s exact test).
DISCUSSION
Persons with PD want to be actively involved in the decision-
making process for an advanced treatment. This observation is
in line with the notion that persons with PD in general want
to be involved in decision-making (9, 17). However, it contrasts
with a study showing that persons with PD prefer a less active
role when confronted with hypothetical decisions, when their
illness progresses (18). The latter applies to our population of
people with advanced PD, of whom 72% had a disease duration
of more than 10 years. One of the reasons for a less active
role when disease progresses is that patients develop cognitive
impairments which would limit their decision-making capacities
(5, 18, 19). It is possible that, due to selection bias in our
population, our respondents did not have cognitive deficits. No
reliable test for subjective cognitive impairment in PD is available
yet and objective cognitive tests are impossible in a self-reported
questionnaire (20). However, mild dementia is considered to be
one of the most important non-motor symptom indicators of
advanced PD (20, 21), and it is therefore likely that participants in
our study will have at least some degree of cognitive impairment.
A striking observation is that, although participants
experienced active involvement, only half of them experienced
the role they preferred. In those cases where the preferred and
perceived role did not match, most patients experienced a more
active role than preferred. In more detail, most of these patients
had preferred shared decision-making. Instead, they experienced
taking the decision themselves, with or without input from
the neurologist. It could be a reflection of the experience that
patients did not feel supported by the professional when making
the decision. It highlights the importance of not abandoning
patients to take the decision alone. Instead, one should strive
for shared decision-making, where patients are supported in
exploring their needs and contributing their expertise to the
conversation (22). It could also mean that we should not force
an active role for all patients, as this could cause distress in
patients who genuinely want a less active role (8). We did not
ask the patients explicitly if they wanted the partner/ caregiver
to be involved, because we evaluated that in our qualitative
analysis. We did see that partners and other caregivers are
highly involved as the majority of participants filled in the
questionnaire with a caregiver. The role of the partner is known
to be increasingly important for patients in the advanced stage
and lack of support from a caregiver could be a contraindication
for an advanced therapy (23). Furthermore, caregivers also
participate more actively in treatment decisions when cognitive
impairments increase in the advanced stage (24). This implies
that SDM should be individualized and patients, caregivers and
neurologists should explicitly discuss which role the patient
prefers in the decision process.
To make a shared decision, patients need to know all available
options. Even though patients felt fully informed, only 41%
knew all options. Patients have indicated before that they were
not informed about the advanced treatment options by their
physician (25) and they preferred to receive more information
on the treatment (26). This raises the question whether patients
can truly be involved when they do not know all options.
A more striking finding is that the patient is seemingly
unaware of the missing information as they feel fully informed
and, at the same time, they do not know all options, which
could result in the so-called “silent misdiagnosis” (27). This
phenomenon describes the misdiagnosis about the treatment
preference. Similar to the medical misdiagnosis, the preference
misdiagnosis also harms the patient, when the chosen treatment
does not fit that individual patient. Once patients are better
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FIGURE 1 | Importance and Performance (IPA) analysis. All information attributes are displayed in random order. The attributes in the gray area represent the
information attributes that need improvement. The attributes in the area of “maintain performance” scored high in importance and information provision; those
attributes are sufficiently covered. The attributes in the area of possible overkill’ are attributes that were considered less important but were covered adequately in
information provision. The area of “low priority” represents the attributes that were not sufficiently covered in information provision but were also considered less
important. The information attributes are described in more detail in the questionnaire (Supplement 1).
informed, they often choose a different therapy (27). PD patients
in the advanced stage without advanced therapy indicated that
the reason they were not on advanced therapy was that they
needed more time to decide (23). It is not clear why the patients
needed more time to decide, but it suggests a need for better
guidance during the decision-making process.
When we evaluated which information is needed to make the
decision, PD patients showed very diverse information needs and
they considered almost all attributes to some extent important.
Patients weigh the benefits and harms of the options differently
(17), which means there is no general information strategy that
can be applied. This requires an individual approach to identify
the key information attributes that need to be discussed with
each patient.
The information on effects of the advanced treatments on
quality of life had the highest importance score and scored
low on performance. The lowest performance scores were given
for information on long term effects and psychological effects
of the advanced treatments. Clinicians can use these outcomes
on performance scores as a starting point to improve the
information provision and can use their skills to adjust the
information to the needs to the individual patient.
Improving the knowledge of patients on all options alone,
however, will not be sufficient to improve SDM, as other factors
also facilitate or hinder SDM according to the participants.
The facilitators in the top five were at the patient’s level,
professional’s level, and the level of the patient- professional
interaction. Patients noted themselves that if they felt that it
is their decision, this supports them to actively participate
in decision-making. It requires a context where the patient
feels empowered to uptake that active role (28). At the
professional level, the experience of the neurologist with the
treatments was considered a very important facilitator and
the professional taking time for the decision process also
stimulated the patient to become involved. The facilitators at
the interpersonal level include trust between the patient and
neurologist, and having an open discussion in the decision
process. Because PD patients who are eligible for an advanced
treatment often already have a well-established and trustful
relationship with their neurologist, this is a good foundation for
SDM (26).
Unlike the agreement among patients regarding factors that
facilitate SDM, they did not often point out factors that
hampered SDM. One of the reasons could be that a large
percentage of our population experienced an active role and
therefore did not experience barriers to SDM. The top five
barriers represented the patient’s level (i.e., patient feeling
there is no choice), professional’s level (i.e., the professional’s
own treatment preference), and at the organizational level
(i.e., lack of time during consultation, multiple professionals
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involved, and lack of research on all treatments). The most
frequently rated barrier by the patients was that they did not
experience a choice. The observed lack of knowledge about
all treatment options among patients might have induced
the feeling that there was nothing to choose from. Various
factors were identified that contribute to this knowledge
gap: first of all, there is no evidence from studies that
directly compare the three treatments. Secondly, the neurologist
can have limited experience with one or two treatment
options, for example because not all options can be offered
in their own hospital (5). Thirdly, when the neurologist
has a clear own preference, the information sharing will
inevitably be biased. All these factors increase the power
imbalance between the patient and professional, hampering
SDM (28, 29).
To improve the implementation of SDM for choosing an
advanced treatment, steps have already been taken to improve
the neurologist’s expertise by defining patient profiles for
suitability of the advanced treatments (21). The information
for the patient should also be provided in a transparent way,
to reduce the influence of the (possible biased) experience
of the individual neurologist with the treatments. There is
a need for more guidance during this decision process to
prevent patients from deferring a decision or not make a
decision for an advanced treatment at all (23). This can be
realized by developing a decision support tool, for example, that
presents the options in a clear, meaningful manner, and supports
patients in constructing their preferences (30). Additionally,
the interactional context between patient and professional is
equally important to improve SDM. From our facilitator ranking
exercise, it appeared that training professionals to improve their
interpersonal skills is needed. To improve the communication
during the decision-making process, the neurologist and PD
nurse specialist should be trained in skills to support and
facilitate the patient to express their needs and preferences
and to clarify which role the patient prefers. Improvements in
the organizational structure are necessary to give time for the
decision process and to have a limited number of professionals
involved. However, what type of trainings or interventions are
most effective to increase the use of SDM by neurologists
is unclear due to low level evidence (31) and should be
further investigated.
Strengths and Limitations
The major strength of this study is that it quantitatively
analyzed the decision-making process for advanced treatments
in PD. Earlier, we qualitatively evaluated the decision-making
process, which led to a large set of information needs that
could be improved, as well as a large number of facilitators
and barriers to improve the implementation SDM. In the
current study, we prioritized information needs and barriers
and facilitators for SDM, which helps us to develop a tailored
implementation strategy.
A limitation of the study is that we asked the preferred
and experienced roles in decision-making retrospectively. To
increase the number of available patients, we included patients
that started treatment in the previous 3 years. This, however,
increases the risk of recall bias. For the congruence between
the preferred role and the perceived role, specifically, we found
that in other retrospective studies this congruence was slightly
higher with 63% (32). It is argued that congruence increases in
retrospective studies because of the decision evaluation of the
patient and the desire of the patient for congruence, introducing
cognitive bias (32). This could mean that the congruence in our
population is an overestimation, compared to if we would have
tested it prospectively.
Another limitation is the lack of knowledge on the cognitive
status of our participants. As moderate to severe dementia is
considered a contraindication for all therapies (21), we can
assume that the patients did not have severe dementia at the time
of decision. However, we cannot exclude that some patients have
developed dementia after start of treatment and that this would
have influenced their responses. In our ongoing prospective
observational study of the decision process for an advanced
treatment, we therefore evaluate the cognitive status of all
participants (33).
Finally, many respondents (up to 16%) did not rate the list of
facilitators and/or barriers for SDM. We could not find different
characteristics for the group with most missing values compared
to the rest of the participants, except for gender. An explanation
for the large number of missing values for this topic in the
questionnaire could be response fatigue, as the rating of the
barriers and facilitators was one of the last topics (34). We
anticipated partly on this beforehand with changing the order of
barriers and facilitators in the two versions of the questionnaire.
Another explanation could be that the questions were unclear
or that the concepts of barriers and facilitators to SDM were
difficult to understand, however, we clarified this concept in the
questionnaire and no difficulties in understanding the questions
emerged in the pre-test. As the missing values were equally
divided across all items, they do not affect the interpretation of
the importance ranking of each facilitator/barrier.
CONCLUSIONS
Our study has shown that patients highly value SDM when
choosing an advanced treatment option. The study also has
revealed the current limitations of patient participation. One
of the most important risks is that patients feel involved
but are unaware of all options and information needs are
not adequately addressed. Improvement of patient involvement
could be achieved by creating a decision support tool that
provides balanced information on all options, increasing the
expertise of the neurologist, increasing the SDM skills of the
neurologist, and improving the organizational context. How this
can be best achieved has to be evaluated in further research.
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